## UK NEQAS Leucocyte Immunophenotyping

### www.ukneqasli.co.uk

# New Information for 2021/2022

EQA Programmes for Molecular Haemato-Oncology



www.eqainternational.com

Working in partnership with UK NEQAS LI

#### BCR-ABL1 Kinase Domain Variant (Mutation) Status programme

The *BCR-ABL1* Kinase Domain Variant (Mutation) Status programme is now ISO 17043 accredited and subject to performance monitoring. Please refer to the website www. ukneqasli.co.uk for further information regarding the qualitative scoring system. This incorporates HGVS nomenclature recommendations adherence criteria. Distributions will increase to 3 trial issues per annum for 2021/22.

#### **FLT3** Mutation Status

The submission of allelic ratio information (mutant/wildtype) based on European Leukaemia Network guidelines (Döhner et al., 2017) will continue to be required. However, this will be through the participant hub data entry pages, rather than external JotForm submissions. As such, there will be some changes to the data entry page for this programme.

#### **BCR-ABL1** Major Quantification

UK NEQAS LI have been piloting a new method for the generation of robust statistics and performance scores based on single sample results. This will become the primary performance monitoring system in 2021/2022, replacing the current system based on the log reduction between samples. The new method uses robust statistics and z-scores in line with other accredited UK NEQAS LI programmes. To achieve this, the data is first log transformed to create normalised data distribution to which robust statistical analysis can then be undertaken.

#### IgH/TCR Clonality Status

As a response to feedback, participants will now be allowed to provide an `optional more detailed molecular interpretations' response (Langerak et al., 2012) to supplement the overall technical description (final molecular conclusion) on which participants are currently scored. These descriptions contain more details with respect to biallelic products, minor clonal products, or an oligo/polyclonal background.

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI Pegasus House 4<sup>th</sup> Floor Suite 463a Glossop Road Sheffield S10 2QD United Kingdom

Tel: +44 (0)114 2673600 | Fax: +44 (0)114 2673601 email: admin@ukneqasli.co.uk | www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor (and is outside of the UK) you should contact them directly for details of how to register.